<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Design and Evaluation of Complex Sequential Analysis Trials</title>

<script src="site_libs/header-attrs-2.28/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="02-Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="03-SSC-Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="03-SSC-Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="03-SSC-Biosimilar-Trials.html">Statistical Considerations for the Design and Analysis of Biosimilar Trials</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
    <li>
      <a href="03-SSC-Power-for-Complex-Hypotheses.html">Power for Complex Hypotheses</a>
    </li>
    <li>
      <a href="03-SSC-Alternatives-to-Power.html">Bayesian methods - Alternatives to Power</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-for-Pilot-Studies.html">Sample Size for Pilot Studies</a>
    </li>
    <li>
      <a href="03-SSC-Case-Continuous-Endpoint.html">Sample Size Determination for Continuous Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Categorical-Endpoint.html">Sample Size Determination for Categorical Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Survival-Endpoint.html">Sample Size Determination for Survival Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Repeated-Measures.html">Sample Size Determination for Repeated Measures</a>
    </li>
    <li>
      <a href="03-SSC-IA-Sequential-Design.html">Statistical Considerations for Group Sequential Design</a>
    </li>
    <li>
      <a href="03-SSC-IA-Adaptive-Design.html">Statistical Considerations for Adaptive Design</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="04-Design-Estimands-Framework.html">Estimands Framework</a>
    </li>
    <li>
      <a href="04-Design-Estimands-Practice.html">Estimands and Sensitivity Analyses</a>
    </li>
    <li>
      <a href="04-Design-Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="04-Design-Complex-Sequential-Trials.html">Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="04-Design-Adaptive-Clinical-Trials.html">Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Bayesian-Clinical-Trials.html">Bayesian Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="04-Design-Single-Arm-Clinical-Trials.html">Single Arm Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-Design-and-Evaluation.html">Diagnostic Study-Design and Evaluation</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-MRMC.html">Diagnostic Study-Multireader Multicase (MRMC)</a>
    </li>
    <li>
      <a href="04-Design-Hierarchical-composite-endpoints.html">Hierarchical Composite Endpoints</a>
    </li>
    <li>
      <a href="04-Design-Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="04-Design-Noninferiority-Trials.html">Noninferiority Trials</a>
    </li>
    <li>
      <a href="04-Design-Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="04-Design-Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
    <li>
      <a href="04-Design-Regulatory-Submission.html">Regulatory Submission from Stats Perspective</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="05-Plot-Adverse-Event.html">Adverse Event Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Laboratory-Data.html">Laboratory Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Time-To-Event.html">Time to Event Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-PRO-Data.html">Patient Reported Outcome Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-SSC-and-Power-Calculation.html">Sample Size and Power Calculations Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Correlation.html">Correlation Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Model-Table.html">Clinical Data and Model visualization</a>
    </li>
    <li>
      <a href="05-Plot-ScatterPlot.html">Scatter and Line Plot</a>
    </li>
    <li>
      <a href="05-Plot-BarPlot.html">Bar Chart</a>
    </li>
    <li>
      <a href="05-Plot-PieChart.html">Pie Chart</a>
    </li>
    <li>
      <a href="05-Plot-BoxPlot.html">Box Plot</a>
    </li>
    <li>
      <a href="05-Plot-Histogram.html">Histogram</a>
    </li>
    <li>
      <a href="05-Plot-Forest-Plot.html">Forest Plot</a>
    </li>
    <li>
      <a href="05-Plot-Flow-Chart.html">Flow Chart</a>
    </li>
    <li>
      <a href="05-Plot-Some-Interesting.html">Some Interesting Plots</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-calculator"></span>
     
    Statistical Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="06-Analysis-Linear-Regression.html">Linear Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Logistic-Regression.html">Logistic Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Mixed-Model.html">Mixed Model</a>
    </li>
    <li>
      <a href="06-Analysis-MMRM.html">Mixed Model Repeated Measures</a>
    </li>
    <li>
      <a href="06-Analysis-GEE.html">Generalized Estimating Equation</a>
    </li>
    <li>
      <a href="06-Analysis-ANOVA.html">Analysis of Variance</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Competing-Risk.html">Survival Analysis - Competing Risk</a>
    </li>
    <li>
      <a href="06-Analysis-Missing-Data.html">Missing Data Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-MI-Implementation.html">Multiple Imputation Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Meta-Analysis.html">Meta Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-PK-and-PD.html">PK and PD Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Time-Series-Analysis.html">Time Series Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-SEM.html">Structural Equation Modeling</a>
    </li>
    <li>
      <a href="06-Analysis-Factor-Analysis.html">Factor Analysis</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-bar-chart"></span>
     
    Machine Learning
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="07-ML-Bayesian-Theory.html">Bayesian Theory</a>
    </li>
    <li>
      <a href="07-ML-Bayesian-Analysis.html">Bayesian Analysis</a>
    </li>
    <li>
      <a href="07-ML-Regularization-Penalized-Regression.html">Regularization Penalized Regression</a>
    </li>
    <li>
      <a href="07-ML-Loss-Regression.html">Loss Functions in Machine Learning</a>
    </li>
    <li>
      <a href="07-ML-PCA.html">Principal Component Analysis</a>
    </li>
    <li>
      <a href="07-ML-KNN.html">K-Nearest Neighbors</a>
    </li>
    <li>
      <a href="07-ML-SVM.html">Support Vector Machine</a>
    </li>
    <li>
      <a href="07-ML-Tree-Models.html">Tree Models</a>
    </li>
    <li>
      <a href="07-ML-LDA.html">Linear Discriminant Analysis</a>
    </li>
    <li>
      <a href="07-ML-Cluster-Analysis.html">Cluster Analysis</a>
    </li>
    <li>
      <a href="07-ML-Neural-Networks.html">Neural Network</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="08-CV.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
<li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Design and Evaluation of Complex Sequential Analysis Trials</p></h1>

</div>


<div id="group-sequential-design" class="section level2">
<h2>Group Sequential Design</h2>
<p>Group Sequential Design (GSD) is a sophisticated statistical
technique used primarily in clinical trials to evaluate the efficacy or
safety of a new treatment in stages, rather than waiting for the trial’s
conclusion. This approach is particularly beneficial as it allows for
early termination of the trial for efficacy, safety, or futility,
thereby potentially reducing costs and ethical concerns associated with
exposing participants to less effective or harmful treatments.</p>
<div id="key-features-of-group-sequential-design"
class="section level3">
<h3>Key Features of Group Sequential Design</h3>
<ol style="list-style-type: decimal">
<li><p><strong>Interim Analysis</strong>: GSD involves multiple planned
interim analyses of the data. At each of these points, a decision can be
made to continue, modify, or stop the trial based on the results. These
analyses are conducted at pre-specified times or after a certain number
of patients have been observed.</p></li>
<li><p><strong>Statistical Rigor</strong>: The design incorporates
methods to control for Type I (false positive) and Type II (false
negative) errors across the multiple looks at the data. Since every
interim analysis carries a risk of incorrectly rejecting the null
hypothesis (declaring a treatment effective when it is not), GSD uses
specific statistical techniques to adjust the significance
thresholds.</p></li>
<li><p><strong>Error Spending Functions</strong>: These are mathematical
tools used in GSD to allocate the probability of type I and type II
errors across the interim analyses. Well-known functions include the
O’Brien-Fleming and Pocock methods, which differ in how conservatively
they spend the error probabilities. O’Brien-Fleming is more conservative
early in the trial, making it harder to declare early success, while
Pocock allows more evenly distributed error rates across
analyses.</p></li>
<li><p><strong>Flexibility and Adaptability</strong>: GSD is flexible in
that it can adapt to the data as it accumulates. For instance, if
interim results are promising, a trial might be stopped early due to
efficacy, thus speeding up the availability of beneficial treatments to
the public. Conversely, a lack of interim efficacy might lead to an
early trial termination for futility, saving resources and protecting
participants from ineffective treatments.</p></li>
<li><p><strong>Ethical and Practical Advantages</strong>: By potentially
shortening the duration of trials and reducing the number of
participants exposed to inferior treatments, GSD enhances the ethical
conduct of clinical trials. It also helps in faster decision-making,
which is critical in scenarios like pandemics where rapid development
and evaluation of treatments are required.</p></li>
</ol>
</div>
<div id="types-of-group-sequential-design" class="section level3">
<h3>Types of Group Sequential Design</h3>
<ol style="list-style-type: decimal">
<li><p><strong>Error Spending</strong>: Involves allocating the
probabilities of type I (false positive) and type II (false negative)
errors across multiple interim analyses, allowing flexibility in the
design and analysis stages of a clinical trial.</p></li>
<li><p><strong>Haybittle-Peto Method</strong>: A more conservative
approach that defines boundaries for efficacy based on unadjusted
p-values, seeking to preserve the overall Type I error rate across
multiple looks at the data.</p></li>
<li><p><strong>Wang-Tsiatis Parameter Method</strong>: Combines
considerations of efficacy and futility. This method proposes strategies
to optimize the average sample size needed to maintain statistical power
while controlling type I error.</p></li>
<li><p><strong>Classic Designs</strong>: Including well-known methods
like O’Brien-Fleming and Pocock, which set more rigid boundaries and are
less flexible during data monitoring than error spending
methods.</p></li>
<li><p><strong>Unified Family</strong>: Encompasses the Wang-Tsiatis
method and classic designs, offering a two-parameter approach that
provides a balance between flexibility and stringent
monitoring.</p></li>
<li><p><strong>Whitehead’s Sequential Designs</strong>: An extension of
sequential probability ratio tests (SPRT) to settings where decisions
are made at group intervals, often visualized with unique design
patterns like “Triangular” or “Christmas Tree” designs.</p></li>
<li><p><strong>Others</strong>: Custom designs such as Conditional Power
or adaptive designs like Multi-Arm Multi-Stage (MAMS) strategies, which
allow for changes based on interim results without compromising the
integrity of the statistical inference.</p></li>
</ol>
</div>
<div id="complex-survival-group-sequential-designs"
class="section level3">
<h3>Complex Survival Group Sequential Designs</h3>
<p>These designs address the challenges associated with clinical trials
that assess survival outcomes, such as in oncology or chronic disease
studies.</p>
<ul>
<li><p><strong>Patient Follow-up</strong>: Decisions on whether to
continue following patients until the end of the study or for a fixed
period are critical. This affects the timing and reliability of interim
analyses.</p></li>
<li><p><strong>Non-proportional Hazards</strong>: This refers to
situations where the effect of a treatment on survival is not constant
over time. Handling non-proportional hazards requires complex
statistical methods to ensure accurate interpretations.</p></li>
<li><p><strong>Complex Accrual, Survival, Dropout</strong>: Managing
varying rates of patient accrual, different survival rates, and dropout
rates are challenges that can affect the power and statistical validity
of the study.</p></li>
<li><p><strong>Stratified Analyses</strong>: Analyzing subsets of data
stratified by factors like demographics or disease severity can help in
understanding treatment effects more deeply but requires careful
planning to maintain statistical power.</p></li>
</ul>
<p><img src="02_Plots/GSD-Surv.png" width="75%" style="display: block; margin: auto;" /></p>
</div>
<div id="complex-adaptive-group-sequential-designs"
class="section level3">
<h3>Complex Adaptive Group Sequential Designs</h3>
<p>These designs incorporate flexibility that allows modifications to
the trial procedures based on interim results without undermining the
integrity of the study.</p>
<ul>
<li><p><strong>Treatment Arms</strong>: Multi-Arm Multi-Stage (MAMS)
designs are used to evaluate several treatment arms simultaneously.
Ineffective treatments can be dropped early (“Drop the loser”), and
potentially effective treatments can be identified sooner (“Pick the
winner”).</p></li>
<li><p><strong>Sample Size</strong>: Bayesian Sample Size Re-estimation
(BSSR) or Frequentist approaches like the Unconditional Sample Size
Re-estimation (USSR) can adjust the sample size based on interim data to
maintain adequate power or precision.</p></li>
<li><p><strong>Patient Subgroups</strong>: Identifying which subgroups
of patients benefit most from the treatment can lead to more
personalized medicine approaches but requires sophisticated statistical
techniques to analyze effectively.</p></li>
<li><p><strong>Bayesian Approach</strong>: Using Bayesian statistics can
provide a more flexible and comprehensive analysis of data through the
incorporation of prior knowledge and real-time data updating, which is
particularly useful in adaptive designs.</p></li>
</ul>
<p><img src="02_Plots/GSD-mams-graphic.png" width="75%" style="display: block; margin: auto;" /></p>
</div>
</div>
<div id="group-sequential-design-simulation" class="section level2">
<h2>Group Sequential Design Simulation</h2>
<p>Simulation in the context of Group Sequential Design (GSD) provides a
critical tool for designing and analyzing complex clinical trials. The
process employs simulated study data to predict and verify the
characteristics of a GSD. This approach is particularly important for
understanding the implications of advanced GSDs and ensuring the
robustness of the study before actual implementation.</p>
<div id="benefits-of-gsd-simulation" class="section level3">
<h3>Benefits of GSD Simulation</h3>
<ul>
<li><p><strong>Complex GSD Understanding</strong>: Simulations help in
comprehending the outcomes and behaviors of complex GSDs, which might be
difficult to predict using traditional analytical methods due to their
sophisticated and flexible nature.</p></li>
<li><p><strong>Verification of Design</strong>: It allows for the
verification of the original design, ensuring that the planned
parameters are appropriate for achieving the desired statistical power
and maintaining control over Type I and Type II errors.</p></li>
<li><p><strong>Exploration of Scenarios</strong>: Simulations can test
various scenarios including different rates of patient accrual,
variations in treatment effects, and changes to the timing and frequency
of interim analyses. This helps in optimizing the design by considering
a range of possible outcomes.</p></li>
<li><p><strong>Regulatory Approval</strong>: Given the complexity and
the high stakes involved in clinical trials, regulatory bodies often
view positively the use of simulation to demonstrate the robustness and
reliability of a GSD. It aids in the approval process by showing that
the trial design can effectively manage potential risks and
uncertainties.</p></li>
</ul>
</div>
<div id="steps-in-designing-simulated-gsd" class="section level3">
<h3>Steps in Designing Simulated GSD</h3>
<ol style="list-style-type: decimal">
<li><strong>Generating Model Assumptions</strong>: This involves
defining the underlying statistical distributions and parameters that
reflect the clinical scenario being studied. Assumptions might include
the expected effect size of the treatment, variance, and patient
response distribution.</li>
</ol>
<p><img src="02_Plots/GSD-Simulation-Step1.png" width="75%" style="display: block; margin: auto;" /></p>
<ol start="2" style="list-style-type: decimal">
<li><strong>Design Assumptions</strong>: Set up the structural aspects
of the trial, such as the number and timing of interim analyses, the
criteria for continuing or stopping the trial, and the methods for
adjusting the estimates based on interim results.</li>
</ol>
<p><img src="02_Plots/GSD-Simulation-Step2.png" width="75%" style="display: block; margin: auto;" /></p>
<ol start="3" style="list-style-type: decimal">
<li><p><strong>Boundary/Information Assumptions</strong>: Determine the
statistical thresholds (boundaries) for making decisions at each interim
analysis. This involves setting the alpha and beta spending functions
that dictate how the error probabilities are allocated throughout the
trial.</p></li>
<li><p><strong>Simulation Control Assumptions</strong>: Define the rules
for running the simulation, including the number of simulations, the
method for generating data, and the criteria for evaluating the outcomes
of each simulated iteration.</p></li>
</ol>
</div>
<div id="implementation-in-r" class="section level3">
<h3>Implementation in R</h3>
<pre><code>## Asymmetric two-sided group sequential design with
## 90 % power and 2.5 % Type I Error.
## Upper bound spending computations assume
## trial continues if lower bound is crossed.
## 
##                   ----Lower bounds----  ----Upper bounds-----
##   Analysis   N    Z   Nominal p Spend+  Z   Nominal p Spend++
##          1  123 -0.83    0.2041  0.025 3.14    0.0008  0.0008
##          2  489  0.39    0.6513  0.025 3.16    0.0008  0.0008
##          3  855  1.26    0.8966  0.025 3.06    0.0011  0.0009
##          4 1222  1.98    0.9761  0.025 1.98    0.0239  0.0225
##      Total                      0.1000                 0.0250 
## + lower bound beta spending (under H1):
##  User-specified spending function with Points = 0.25, Points = 0.5, Points = 0.75, Points = 1.
## ++ alpha spending:
##  User-specified spending function with Points = 0.03333, Points = 0.06337, Points = 0.1, Points = 1.
## 
## Boundary crossing probabilities and expected sample size
## assume any cross stops the trial
## 
## Upper boundary (power or Type I Error)
##           Analysis
##    Theta      1      2      3      4  Total  E{N}
##   0.0000 0.0008 0.0007 0.0009 0.0177 0.0202 564.0
##   0.1025 0.0222 0.1716 0.2969 0.4094 0.9000 907.4
## 
## Lower boundary (futility or Type II Error)
##           Analysis
##    Theta      1      2      3      4  Total
##   0.0000 0.2041 0.4703 0.2361 0.0693 0.9798
##   0.1025 0.0250 0.0250 0.0250 0.0250 0.1000</code></pre>
<p><img src="04-Design-Complex-Sequential-Trials_files/figure-html/unnamed-chunk-5-1.png" width="960" /><img src="04-Design-Complex-Sequential-Trials_files/figure-html/unnamed-chunk-5-2.png" width="960" /></p>
</div>
</div>
<div id="survival-group-sequential-design" class="section level2">
<h2>Survival Group Sequential Design</h2>
<div id="power-for-survival-analysis" class="section level3">
<h3>Power for Survival Analysis</h3>
<p>Power calculations in survival analysis are influenced by several key
choices:</p>
<ol style="list-style-type: decimal">
<li><strong>Design Choices</strong>: Including the structure of the
trial (parallel, one-arm, or complex designs).</li>
<li><strong>Statistical Methods</strong>: Such as the log-rank test or
Cox proportional hazards model, which are common in survival analysis
for comparing the survival times of different groups.</li>
<li><strong>Endpoints</strong>: Typically involves the hazard ratio or
survival time, directly impacting how the analysis interprets and values
outcomes.</li>
<li><strong>Survival Distribution Models</strong>: Including exponential
or Weibull distributions which assume different forms of the hazard
function over time.</li>
</ol>
<p>The primary driver for statistical power in survival analysis is the
number of events (e.g., deaths, disease progression), not just the
sample size. This is because the statistical methods used often depend
more directly on the number of events to detect a true effect.</p>
</div>
<div id="key-equations-and-concepts" class="section level3">
<h3>Key Equations and Concepts</h3>
<ul>
<li><p><strong>Schoenfeld (1981)</strong> and <strong>Freedman
(1982)</strong> provide formulas to estimate the required number of
events or total sample size based on desired power and effect size,
incorporating adjustments for multiple interim analyses.</p></li>
<li><p><strong>Lachin &amp; Foulkes (1986)</strong> offer an expression
for expected number of events given non-uniform accrual rates, dropout
rates, and other complexities.</p></li>
<li><p><strong>Lakatos (1988)</strong> provides a matrix method for
estimating the required sample size, accommodating various rates and
probabilities that influence survival analysis.</p></li>
<li><p><strong>Y. Tang (2021/2022)</strong> introduces a method for
estimating variance components in complex survival models, which is
useful in planning and analyzing survival data under various assumptions
and covariate effects.</p></li>
</ul>
<p>Certainly! The key equations from your slide reflect various methods
used to calculate sample size and number of events for survival analysis
in clinical trials, specifically within the framework of group
sequential design (GSD). Let’s explore these equations in detail:</p>
<div id="schoenfelds-formula-1981" class="section level4">
<h4>1. Schoenfeld’s Formula (1981)</h4>
<p>This formula is used to calculate the number of events needed to
achieve a desired power in a survival study:</p>
<p><span class="math display">\[ E = \frac{(z_{\alpha/2} +
z_{\beta})^2}{[\ln(h)]^2} \]</span></p>
<ul>
<li><strong><span class="math inline">\(E\)</span></strong>: Number of
events required.</li>
<li><strong><span class="math inline">\(z_{\alpha/2}\)</span></strong>
and <strong><span class="math inline">\(z_{\beta}\)</span></strong>:
Standard normal deviates corresponding to the Type I error rate (<span
class="math inline">\(\alpha\)</span>) and the power (1-<span
class="math inline">\(\beta\)</span>), respectively.</li>
<li><strong><span class="math inline">\(\ln(h)\)</span></strong>:
Natural logarithm of the hazard ratio. This reflects the expected
difference in the hazard rates between the treatment and control
groups.</li>
</ul>
</div>
<div id="freedmans-formula-1982" class="section level4">
<h4>2. Freedman’s Formula (1982)</h4>
<p>Freedman provided a formula for estimating the sample size needed in
a survival study considering two different survival times under the null
and alternative hypotheses:</p>
<p><span class="math display">\[ n = \frac{(z_{1-\alpha/2} +
z_{1-\beta})^2 (h+1)^2}{(2-x_1 - x_2)(h-1)^2} \]</span></p>
<ul>
<li><strong><span class="math inline">\(n\)</span></strong>: Total
sample size required.</li>
<li><strong><span class="math inline">\(x_1, x_2\)</span></strong>:
Expected proportions surviving in each group at a given time point.</li>
<li><strong><span class="math inline">\(h\)</span></strong>: Hazard
ratio under the alternative hypothesis.</li>
</ul>
</div>
<div id="lachin-foulkes-expected-number-of-events-1986"
class="section level4">
<h4>3. Lachin &amp; Foulkes’ Expected Number of Events (1986)</h4>
<p>This formula helps calculate the expected number of events over time,
accounting for different accrual and dropout rates:</p>
<p><span class="math display">\[ E(p_j) = \frac{\lambda}{4 + d} \left[ 1
- e^{-(4+d)T} - e^{-(4+d)\tau} \right] \]</span></p>
<ul>
<li><strong><span class="math inline">\(\lambda\)</span></strong>:
Initial accrual rate.</li>
<li><strong><span class="math inline">\(d\)</span></strong>: Dropout
rate.</li>
<li><strong><span class="math inline">\(T, \tau\)</span></strong>: Total
follow-up time and interim analysis time, respectively.</li>
</ul>
</div>
<div id="lakatos-matrix-method-for-sample-size-1988"
class="section level4">
<h4>4. Lakatos’ Matrix Method for Sample Size (1988)</h4>
<p>Lakatos introduced a matrix-based method to compute the required
sample size considering various scenarios, represented in matrix form
for simplicity in computations:</p>
<p><span class="math display">\[ L, E, Ac \]</span> - Matrices
<strong><span class="math inline">\(L\)</span></strong>, <strong><span
class="math inline">\(E\)</span></strong>, and <strong><span
class="math inline">\(Ac\)</span></strong> capture different rates and
probabilities impacting the study, such as loss to follow-up, event
probabilities, and accrual rates.</p>
</div>
<div id="tangs-variance-estimation-20212022" class="section level4">
<h4>5. Tang’s Variance Estimation (2021/2022)</h4>
<p>Tang proposed a method for estimating variance in survival models,
essential for planning and analyzing survival data with complex
covariate effects:</p>
<p><span class="math display">\[ \sigma^2 = \int_{0}^{\infty} \left[
\frac{u(t) \phi&#39;(t)}{[\phi(t)/\phi_0(t)] + 1} \right] V(t) \, dt
\]</span></p>
<ul>
<li><strong><span class="math inline">\(\sigma^2\)</span></strong>:
Variance of the estimator.</li>
<li><strong><span class="math inline">\(u(t)\)</span></strong>,
<strong><span class="math inline">\(\phi(t)\)</span></strong>,
<strong><span class="math inline">\(\phi_0(t)\)</span></strong>:
Functions representing the weighting scheme, cumulative hazard function
under the alternative hypothesis, and under the null hypothesis,
respectively.</li>
<li><strong><span class="math inline">\(V(t)\)</span></strong>:
Information matrix which may involve covariates and other model
complexities.</li>
</ul>
<p>Each of these equations plays a critical role in designing survival
analysis studies within a GSD framework, allowing for robust planning
and analysis while considering various uncertainties and complexities
inherent in clinical trial data.</p>
</div>
</div>
<div id="complexities-in-survival-gsd" class="section level3">
<h3>Complexities in Survival GSD</h3>
<ul>
<li><p><strong>Unknown Follow-up</strong>: The uncertainty in follow-up
time makes it difficult to precisely schedule and plan interim analyses,
which are crucial for decision-making in GSDs.</p></li>
<li><p><strong>Interim Analysis Timing</strong>: It’s challenging to
predict exactly when interim analyses will occur, especially in longer
trials where events (like progression or death) determine the
timing.</p></li>
<li><p><strong>Variable Cohort Activity</strong>: At any interim point,
the cohort’s composition might be skewed towards more active (or more
recently recruited) participants, affecting the interim
results.</p></li>
<li><p><strong>Constant Effects vs. Non-Proportional Hazards
(NPH)</strong>: Trials must decide whether to assume that the treatment
effect is constant over time or if it varies, which impacts the choice
of statistical model and interpretation of results.</p></li>
<li><p><strong>Interim Events and Sampling Bias</strong>: Increasing
sample size can bias the detection of early trends, while increasing
follow-up time can bias the capture of later trends, highlighting the
delicate balance needed in trial planning.</p></li>
<li><p><strong>Strategic Planning</strong>: Using approaches like the
Unconditional Sample Size Re-estimation (USSR) proposed by Freidlin
&amp; Korn (2017) can help address some of these complexities by
allowing flexibility in sample size adjustment based on interim
data.</p></li>
</ul>
</div>
</div>
<div id="reference" class="section level2">
<h2>Reference</h2>
<ol style="list-style-type: decimal">
<li>Haybittle, J.L. (1971). “Repeated assessment of results in clinical
trials of cancer treatment.” <em>The British Journal of Radiology</em>,
44, pp. 793-797.</li>
<li>Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R.,
Howard, S.V., Mantel, N., McPherson, K., Peto, J., and Smith, P.G.
(1976). “Design and analysis of randomized clinical trials requiring
prolonged observation of each patient. I. Introduction and design.”
<em>British Journal of Cancer</em>, 34(6), pp. 585–612.</li>
<li>O’Brien, P.C. &amp; Fleming, T.R. (1979). “A multiple testing
procedure for clinical trials.” <em>Biometrics</em>, 35,
pp. 549-556.</li>
<li>Pocock, S.J. (1977). “Group sequential methods in the design and
analysis of clinical trials.” <em>Biometrika</em>, 64(2),
pp. 191–199.</li>
<li>Whitehead, J. &amp; Stratton, I. (1983). “Group Sequential clinical
trials with triangular continuation regions.” <em>Biometrics</em>, 39,
pp. 227-236.</li>
<li>Whitehead, J. (2001). “Use of the Triangular Test in Sequential
Clinical Trials.” In <em>Handbook of Statistics in Clinical
Oncology</em>, pp. 211–228. New York: Marcel Dekker.</li>
<li>Lan, K.K.G., &amp; DeMets, D.L. (1983). “Discrete Sequential
Boundaries for Clinical Trials.” <em>Biometrika</em>, 70(3),
pp. 659–663.</li>
<li>Kim, K., and DeMets, D.L. (1987). “Design and Analysis of Group
Sequential Tests Based on the Type I Error Spending Rate Function.”
<em>Biometrika</em>, 74, pp. 149–154.</li>
<li>Hwang, I.K., Shih, W.J., and DeCani, J.S. (1990). “Group sequential
designs using a family of type I error probability spending functions.”
<em>Statistics in Medicine</em>, 9, pp. 1439-1445.</li>
<li>Lan, K.K.G., Rosenberger, W.F., and Lachin, J.M. (1993). “Use of
Spending Functions for Occasional or Continuous Monitoring of Data in
Clinical Trials.” <em>Statistics in Medicine</em>, 12(23),
pp. 2219–31.</li>
<li>Demets, D.L., &amp; Lan, K.G. (1994). “Interim analysis: the alpha
spending function approach.” <em>Statistics in Medicine</em>, 13(13‐14),
pp. 1341-1352.</li>
<li>Wang, S.K., and Tsiatis, A.A. (1987). “Approximately optimal
one-parameter boundaries for group sequential trials.”
<em>Biometrics</em>, 43, pp. 193-199.</li>
<li>Pampallona, S., Tsiatis, A.A., and Kim, K. (2001). “Interim
monitoring of group sequential trials using spending functions for the
type I and type II error probabilities.” <em>Drug Information
Journal</em>, 35, pp. 1113-1121.</li>
<li>Emerson, S.S., and Fleming, T.R. (1989). “Symmetric Group Sequential
Designs.” <em>Biometrics</em>, 45, pp. 905–923.</li>
<li>Kittelson, J.M., and Emerson, S.S. (1999). “A Unifying Family of
Group Sequential Test Designs.” <em>Biometrics</em>, 55,
pp. 874–882.</li>
<li>Jennison, C., &amp; Turnbull, B.W. (1999). <em>Group sequential
methods with applications to clinical trials</em>. CRC Press.</li>
<li>Gsponer, T., Gerber, F., Bornkamp, B., Ohlssen, D.,
Vandemeulebroecke, M., Schmidli, H. (2014). “A Practical Guide to
Bayesian Group Sequential Designs.” <em>Pharmaceutical Statistics</em>,
13(1), pp. 71-80.</li>
<li>Berry, S.M., Carlin, B.P., Lee, J.J., &amp; Muller, P. (2010).
<em>Bayesian adaptive methods for clinical trials</em>. CRC Press.</li>
<li>ICH E20 Concept Paper. Available at: <a
href="https://database.ich.org/sites/default/files/E20_FinalConceptPaper_2019_1107_0.pdf">https://database.ich.org/sites/default/files/E20_FinalConceptPaper_2019_1107_0.pdf</a>.</li>
<li>Bauer, P., Bretz, F., Dragalin, V., König, F., and Wassmer, G.
(2016). “Twenty‐five years of confirmatory adaptive designs:
opportunities and pitfalls.” <em>Statistics in Medicine</em>, 35(3),
pp. 325-347.</li>
<li>Kelly, P.J., Sooriyarachchi, M.R., Stallard, N., &amp; Todd, S.
(2005). “A practical comparison of group-sequential and adaptive
designs.” <em>Journal of Biopharmaceutical Statistics</em>, 15(4),
pp. 719-738.</li>
<li>Cui, L., Hung, H.J., &amp; Wang, S.J. (1999). “Modification of
sample size in group sequential clinical trials.” <em>Biometrics</em>,
55(3), pp. 853-857.</li>
<li>Mehta, C.R., &amp; Tsiatis, A.A. (2001). “Flexible Sample Size
Considerations under Information Based Interim Monitoring.” <em>Drug
Information Journal</em>, 35, pp. 1095–1112.</li>
<li>Chen, Y.J., DeMets, D.L., &amp; Lan, K.K.G. (2004). “Increasing the
sample size when the unblinded interim result is promising.”
<em>Statistics in Medicine</em>, 23(7), pp. 1023-1038.</li>
<li>Freidlin, B., &amp; Korn, E.L. (2017). “Sample size adjustment
designs with time-to-event outcomes: a caution.” <em>Clinical
Trials</em>, 14(6), pp. 597-604.</li>
<li>Muller, H-H., &amp; Schafer, H. (2001). “Adaptive group sequential
designs for clinical trials: Combining the advantages of adaptive and of
classical group sequential approaches.” <em>Biometrics</em>, 57,
pp. 886-891.</li>
<li>Wassmer, G. (2006). “Planning and analyzing adaptive group
sequential survival trials.” <em>Biometrical Journal: Journal of
Mathematical Methods in Biosciences</em>, 48(4), pp. 714-729.</li>
<li>Zelen, M. (1969). “Play the winner rule and the controlled clinical
trial.” <em>Journal of the American Statistical Association</em>,
64(325), pp. 131-146.</li>
<li>Ghosh, P., Liu, L., Senchaudhuri, P., Gao, P., &amp; Mehta, C.
(2017). “Design and monitoring of multi‐arm multi‐stage clinical
trials.” <em>Biometrics</em>, 73(4), pp. 1289-1299.</li>
<li>Ghosh, P., Liu, L., &amp; Mehta, C. (2020). “Adaptive multiarm
multistage clinical trials.” <em>Statistics in Medicine</em>.</li>
</ol>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
